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Introduction {#jah31638-sec-0004}
============

Atrial fibrillation (AF) is the most frequent significant cardiac arrhythmia and the strongest common risk factor for ischemic stroke.[1](#jah31638-bib-0001){ref-type="ref"} It increases stroke risk 5‐fold and accounts for ≈15% of all strokes in the United States.[2](#jah31638-bib-0002){ref-type="ref"}, [3](#jah31638-bib-0003){ref-type="ref"} Moreover, strokes caused by AF are more likely to prove fatal or severely disabling.[4](#jah31638-bib-0004){ref-type="ref"}, [5](#jah31638-bib-0005){ref-type="ref"} High‐quality anticoagulant therapy can largely prevent AF‐associated thromboembolic events while minimizing bleeding risk.[6](#jah31638-bib-0006){ref-type="ref"} AF patients taking warfarin are at the lowest risk for both thromboembolism and intracranial hemorrhage at International Normalized Ratio (INR) levels of 1.8 to 3.5, a range that includes the guideline‐recommended range of 2.0 to 3.0.[7](#jah31638-bib-0007){ref-type="ref"}, [8](#jah31638-bib-0008){ref-type="ref"} Frequent INR monitoring with dose adjustment is generally needed to maintain INR levels in this target range of 2.0 to 3.0.[9](#jah31638-bib-0009){ref-type="ref"} Recently developed novel anticoagulants (ie, dabigatran, rivaroxaban, apixaban, and edoxaban) now compete with warfarin as the primary stroke‐preventive therapy for AF patients. These agents offer fixed oral doses without the need for frequent INR monitoring and with a reduced risk of intracranial hemorrhage compared with average to poor warfarin anticoagulation control.[10](#jah31638-bib-0010){ref-type="ref"} These novel agents appear to be particularly attractive for AF patients starting anticoagulant therapy. What remains unclear is whether AF patients who are well anticoagulated on warfarin should switch to a novel agent.

Time in the therapeutic range (TTR) of INR 2.0 to 3.0 is the standard means of assessing quality of warfarin therapy.[11](#jah31638-bib-0011){ref-type="ref"} Secondary analyses of randomized trials indicate that warfarin at TTR ≥70% has efficacy and safety comparable to novel anticoagulants, suggesting that patients with TTR ≥70% would gain little clinical benefit from switching to a novel anticoagulant.[12](#jah31638-bib-0012){ref-type="ref"}, [13](#jah31638-bib-0013){ref-type="ref"}, [14](#jah31638-bib-0014){ref-type="ref"} This assumes, however, that such a high TTR is stable over time. Limited analyses have examined the stability of TTR in AF patients taking warfarin over a prolonged period.[15](#jah31638-bib-0015){ref-type="ref"}, [16](#jah31638-bib-0016){ref-type="ref"}, [17](#jah31638-bib-0017){ref-type="ref"} Our study aimed to address this knowledge gap by assessing the stability of high‐quality anticoagulation over 12 months among patients initiating warfarin. Specifically, we used a large, real‐world cohort of AF patients newly taking warfarin to determine the percentage of patients with an initial 6‐month TTR (TTR~1~) ≥70% whose TTR persisted at ≥70% in the subsequent 6‐month period (TTR~2~). We then assessed patient features potentially predicting continued high‐quality TTR. Addressing these aims can provide guidance to patients and their providers when making the decision to continue warfarin or to switch to a novel agent.

Methods {#jah31638-sec-0005}
=======

Cohort Assembly {#jah31638-sec-0006}
---------------

The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) cohort consists of 13 559 adults diagnosed with nonvalvular AF who received care at Kaiser Permanente Northern California, a large integrated health care delivery system. Details of cohort identification have been described previously.[18](#jah31638-bib-0018){ref-type="ref"} Briefly, patients were identified between July 1, 1996, and December 31, 1997, by searching outpatient databases in which an *International Classification of Diseases, Ninth Revision, Clinical Modification* diagnosis of AF (427.31) was assigned and by searching electrocardiographic databases for diagnoses of AF. Those with at least 1 outpatient diagnosis of AF and an ECG diagnosis of AF were included in the cohort. Index date was defined as the date of first diagnosis of AF during cohort assembly. Patients were followed until September 30, 2003 (median 6.0 years; interquartile range 3.1--6.7 years), and censored at death or disenrollment from the health plan. Exclusion criteria included patients with diagnoses of mitral stenosis, valvular repair or replacement, transient postoperative AF, or concurrent hyperthyroidism to limit the cohort to those with nontransient, nonvalvular AF.

The study was approved by the institutional review boards of the collaborating institutions. Waiver of informed consent was obtained due to the nature of the study.

Study Variables {#jah31638-sec-0007}
---------------

Our analysis focused exclusively on AF patients who were new and continuous users of warfarin. Warfarin status was assessed based on dispensed warfarin prescriptions and outpatient INR values in automated pharmacy and laboratory databases and was validated against warfarin status documented in medical records of potential outcome events.[19](#jah31638-bib-0019){ref-type="ref"} New users were defined as patients with a new prescription for warfarin during the cohort assembly period who had no prior identified warfarin prescription and \<2 outpatient INR measurements in the previous 12 months.[19](#jah31638-bib-0019){ref-type="ref"} Continuous warfarin exposure was defined as periods of \<60 days between the end of the days supplied and the beginning of the subsequent prescription for any 2 consecutive filled prescriptions. For periods \>60 days, continuous warfarin use was assumed if there were intervening INR measurements at least every 42 days. If neither requirement was met, the patient was considered to have discontinued warfarin from day 31 after the end date of the first prescription until the start date of the next prescription. The 30‐day grace period was provided to account for reductions in dose or skipped doses.

TTR is the percentage of time an AF patient maintains an INR between 2.0 and 3.0. Using each patient\'s INR data, we calculated individual patient TTRs via the standard Rosendaal interpolation method for both an initial 6‐month period and the subsequent 6‐month period.[20](#jah31638-bib-0020){ref-type="ref"} This method defines TTR as the number of person‐days with an INR between 2.0 and 3.0 divided by total number of person‐days for which INR could be interpolated. It assumes that changes between consecutive INR measurements are linear over time. We also provided a TTR for the INR range 1.8 to 3.5; there is empirical evidence that this is the full optimal INR range.[7](#jah31638-bib-0007){ref-type="ref"} Our 12‐month study period excluded the first 3 months of warfarin use; this is a "break‐in" period during which optimal warfarin dosing is sought. The initial period was defined as months 4 to 9 inclusive, providing our measures of TTR~1~, and the subsequent period was defined as months 10 to 15 inclusive, providing TTR~2~. We excluded the 8.1% of time on warfarin during which the inter‐INR interval was \>8 weeks.[21](#jah31638-bib-0021){ref-type="ref"} Characteristics of patients with and without 9 months of continuous warfarin use following initial prescription are shown for reference in Table S1.

Covariates included demographic features, risk factors for stroke in patients with AF, the CHA~2~DS~2~‐VASc and ATRIA stroke risk scores, a current or past diagnosis of cancer (excluding nonmelanoma skin cancer), and common rate and rhythm control drugs used in AF. Covariates were identified using clinical inpatient and ambulatory visit, administrative, and pharmacy databases for the 5 years before each patient\'s cohort index date. Diabetes mellitus was identified using a validated diabetes registry.[18](#jah31638-bib-0018){ref-type="ref"} Ascertainment of individual stroke risk factors was validated against a review of samples of outpatient medical records; crude agreement was high (78--96%), and corresponding κ statistics ranged from 0.51 to 0.89.[21](#jah31638-bib-0021){ref-type="ref"}

Statistical Analysis {#jah31638-sec-0008}
--------------------

TTR was first assessed as a continuous variable, summarized using mean with standard deviation and median with interquartile range (quartiles 1--3). We dichotomized TTR at 70%. We assessed patient features correlated with TTR~1~. Among those patients with an initial TTR ≥70%, we recorded the distribution of TTR values in the second 6‐month period (TTR~2~). We assessed the univariate and multivariable associations of clinical features with persistence of TTR ≥70% and with marked deterioration of TTR (ie, TTR \<50%). In sensitivity analyses, we included patients with TTR~1~ ≥70% who discontinued warfarin in the second 6‐month period as part of a composite outcome of deterioration (ie, TTR \<50% or discontinued warfarin). We did not include the following categories of patients in the analysis of TTR~2~: (1) patients who died in the second period (n=16); (2) patients who discontinued warfarin in period 2 but who restarted warfarin \>1 year later (n=42); (3) patients for whom the study follow‐up ended before their second period was complete (n=33); (4) patients who had no interpolatable INR values in period 2 (n=17); and (5) patients who ended their health plan membership during period 2 (n=3). Statistical significance of univariate associations was assessed via chi‐square tests. Features with a univariate association of *P*≤0.20 were entered into logistic regression models. In these models, *P*≤0.05 was considered statistically significant.

All analyses were conducted using SAS statistical software, version 9.4 (SAS Institute Inc).

Results {#jah31638-sec-0009}
=======

Of the 13 559 patients in the ATRIA cohort, 4460 met the criteria for new starts on warfarin during the study period. Of these, 2928 had ≥9 months of continuous warfarin use, including our initial 3‐month dose‐finding period and our first period assessing TTR (months 4--9). There were 2841 patients who had interpolatable INR values (ie, calculable TTR values) in period 1 (Figure [1](#jah31638-fig-0001){ref-type="fig"}). Of those, 43% were aged ≥75 years at baseline, 56% were men, 87% were white, 16% had diabetes mellitus, 55% had hypertension, 28% had coronary artery disease, 27% had heart failure, and 12% had diminished renal function (estimated glomerular filtration rate \<45 mL/min per 1.73 m^2^), among other features. Moreover, 79% had a CHA~2~DS~2~‐VASc score[22](#jah31638-bib-0022){ref-type="ref"} ≥2, and 49% had an ATRIA stroke risk score[23](#jah31638-bib-0023){ref-type="ref"} ≥6 (Table [1](#jah31638-tbl-0001){ref-type="table-wrap"}).

![Selection of study cohort. Of the 13 559 patients in the ATRIA AF cohort, 4460 met the criteria for new starts on warfarin during the study period. Of these, 2928 had ≥9 months of continuous warfarin use, including our initial 3‐month dose‐finding period and our first period assessing TTR (months 4--9). There were 2841 patients who had interpolatable INR values (ie, calculable TTR values) in period 1. From these, we identified the 1156 patients newly started on warfarin and who had a TTR ≥70% in period 1 (TTR ~1~, months 4--9). The primary analysis focused on the 987 patients who had TTR ~1~ ≥70% and had a calculable TTR in period 2 (TTR ~2~, months 10--15). In a sensitivity analysis, we also included the 58 patients with TTR ~1~ ≥70% who discontinued warfarin in period 2. We did not include the following categories of patients in the analysis of TTR ~2~: (1) died in period 2 (n=16), (2) discontinued warfarin in period 2 but restarted warfarin within 1 year (n=42), (3) period 2 follow‐up was incomplete because the study ended (n=33), (4) no interpolatable INR values in period 2 (n=17), and (5) disenrolled in the health plan during period 2 (n=3). AF indicates atrial fibrillation; ATRIA, anticoagulation and risk factors in atrial fibrillation; INR, International Normalized Ratio; TTR, time in the therapeutic range.](JAH3-5-e003482-g001){#jah31638-fig-0001}

###### 

Features of ATRIA Cohort Patients Initiating Warfarin Therapy and Continuing to Take Warfarin Therapy for at Least 9 Months

  Variable[a](#jah31638-note-0003){ref-type="fn"}                               All Patients, n (%)
  ----------------------------------------------------------------------------- ---------------------
  All                                                                           2841 (100)
  Age                                                                           
  \<75 y                                                                        1614 (56.8)
  ≥75 y                                                                         1227 (43.2)
  Sex                                                                           
  Men                                                                           1597 (56.2)
  Women                                                                         1244 (43.8)
  Race                                                                          
  White                                                                         2478 (87.2)
  Other                                                                         363 (12.8)
  Diabetes mellitus                                                             466 (16.4)
  Hypertension                                                                  1575 (55.4)
  Coronary heart disease                                                        797 (28.1)
  Heart failure                                                                 752 (26.5)
  Peripheral artery disease                                                     71 (2.5)
  Renal impairment[b](#jah31638-note-0004){ref-type="fn"}                       351 (12.4)
  Prior stroke                                                                  262 (9.2)
  Cancer                                                                        337 (11.9)
  Prior bleed                                                                   154 (5.4)
  Beta blockers                                                                 945 (33.3)
  Antiarrhythmics                                                               469 (16.5)
  Calcium channel blockers                                                      744 (26.2)
  ATRIA stroke risk score at admission[c](#jah31638-note-0005){ref-type="fn"}   
  0--5                                                                          1455 (51.2)
  6                                                                             404 (14.2)
  ≥7                                                                            982 (34.6)
  CHA~2~DS~2~‐VASc score at admission[d](#jah31638-note-0006){ref-type="fn"}    
  0                                                                             161 (5.7)
  1                                                                             439 (15.5)
  ≥2                                                                            2241 (78.9)

ATRIA indicates anticoagulation and risk factors in atrial fibrillation; eGFR, estimated glomerular filtration rate; ESRD, end‐stage renal disease.

Variables assessed at the beginning of the 15‐month follow‐up period.

eGFR \<45 mL/min/1.73 m^2^ or ESRD.

ATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart failure, hypertension, proteinuria, and eGFR \<45 mL/min/1.73 m^2^ or ESRD.[23](#jah31638-bib-0023){ref-type="ref"}

CHA~2~DS~2~‐VASc score includes congestive heart failure; hypertension; age; diabetes mellitus; stroke, transient ischemic attack, or thromboembolism; vascular disease; and sex.[22](#jah31638-bib-0022){ref-type="ref"}

For these 2841 new and continuous warfarin users, the mean TTR~1~ was 61.7% (SD 24.2%) and the median was 64.1% (interquartile range 45.7--80.1%). In total, 1156 (40.7%) achieved TTR~1~ ≥70% in the initial period, whereas 29.5% demonstrated poor control (TTR~1~ \<50%) (Table [2](#jah31638-tbl-0002){ref-type="table-wrap"}). Most patient features were unrelated to initial TTR ≥70%, although patients with renal impairment had statistically significantly lower TTR~1~, and patients taking beta blockers had borderline significantly higher TTR~1~ (Table [3](#jah31638-tbl-0003){ref-type="table-wrap"}). In a multivariable logistic model, impaired renal function was the sole significant correlate of TTR~1~, with an adjusted odds ratio of 0.77 (95% CI 0.61--0.98) for TTR~1~ ≥70%.

###### 

Distribution of TTR~1~ (Months 4--9) for 2841 New Warfarin Users[a](#jah31638-note-0008){ref-type="fn"}

  TTR~1~ Category   n (%)
  ----------------- -------------
  ≥70%              1156 (40.7)
  65--69%           225 (7.9)
  60--64%           213 (7.5)
  50--59%           410 (14.4)
  \<50%             837 (29.5)

TTR~1~ indicates time in the therapeutic range during the first 6‐month period.

Months 4--9 are the first 6‐month period after the initial 3‐month period to establish a stable warfarin dose.

###### 

Association of Patient Baseline Features With TTR ≥70% in Period 1

  Variable[a](#jah31638-note-0010){ref-type="fn"}                              n      Patients With TTR ≥70% in Months 4--9, n (%)   *P* Value[b](#jah31638-note-0011){ref-type="fn"}
  ---------------------------------------------------------------------------- ------ ---------------------------------------------- --------------------------------------------------
  All                                                                          2841   1156 (40.7)                                    
  Age                                                                                                                                0.45
  \<75 y                                                                       1614   647 (40.1)                                     
  ≥75 y                                                                        1227   509 (41.5)                                     
  Sex                                                                                                                                0.99
  Men                                                                          1597   650 (40.7)                                     
  Women                                                                        1244   506 (40.7)                                     
  Race                                                                                                                               0.44
  White                                                                        2478   1015 (41.0)                                    
  Other                                                                        363    141 (38.8)                                     
  Diabetes mellitus                                                                                                                  0.27
  No                                                                           2375   977 (41.1)                                     
  Yes                                                                          466    179 (38.4)                                     
  Hypertension                                                                                                                       0.65
  No                                                                           1266   521 (41.2)                                     
  Yes                                                                          1575   635 (40.3)                                     
  Coronary artery disease                                                                                                            0.43
  No                                                                           2044   841 (41.1)                                     
  Yes                                                                          797    315 (39.5)                                     
  Heart failure                                                                                                                      0.14
  No                                                                           2089   867 (41.5)                                     
  Yes                                                                          752    289 (38.4)                                     
  Peripheral artery disease                                                                                                          0.45
  No                                                                           2770   1124 (40.6)                                    
  Yes                                                                          71     32 (45.1)                                      
  Renal impairment[c](#jah31638-note-0012){ref-type="fn"}                                                                            0.016
  No                                                                           2490   1034 (41.5)                                    
  Yes                                                                          351    122 (34.8)                                     
  Prior stroke                                                                                                                       0.96
  No                                                                           2579   1049 (40.7)                                    
  Yes                                                                          262    107 (40.8)                                     
  Cancer                                                                                                                             0.35
  No                                                                           2504   1011 (40.4)                                    
  Yes                                                                          337    145 (43.0)                                     
  Prior bleed                                                                                                                        0.34
  No                                                                           2687   1099 (40.9)                                    
  Yes                                                                          154    57 (37.0)                                      
  Beta blockers                                                                                                                      0.057
  No                                                                           1896   748 (39.5)                                     
  Yes                                                                          945    408 (43.2)                                     
  Antiarrhythmics                                                                                                                    0.82
  No                                                                           2372   963 (40.6)                                     
  Yes                                                                          469    193 (41.2)                                     
  Calcium channel blockers                                                                                                           0.15
  No                                                                           2097   870 (41.5)                                     
  Yes                                                                          744    286 (38.4)                                     
  ATRIA score at admission[d](#jah31638-note-0014){ref-type="fn"}                                                                    0.76
  0 to 5                                                                       1455   601 (41.3)                                     
  6                                                                            404    164 (40.6)                                     
  ≥7                                                                           982    391 (39.8)                                     
  CHA~2~DS~2~‐VASc score at admission[e](#jah31638-note-0015){ref-type="fn"}                                                         0.79
  0                                                                            161    66 (41.0)                                      
  1                                                                            439    185 (42.1)                                     
  ≥2                                                                           2241   905 (40.4)                                     

ATRIA indicates anticoagulation and risk factors in atrial fibrillation; eGFR, estimated glomerular filtration rate; ESRD, end‐stage renal disease; TTR, time in the therapeutic range.

Variables assessed at the beginning of the 15‐month follow‐up period.

*P* values from chi‐square tests.

eGFR \<45 mL/min/1.73 m^2^ or ESRD.

ATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart failure, hypertension, proteinuria, and eGFR \<45 mL/min/1.73 m^2^ or ESRD.[23](#jah31638-bib-0023){ref-type="ref"}

CHA~2~DS~2~‐VASc score includes congestive heart failure; hypertension; age; diabetes mellitus; stroke, transient ischemic attack, or thromboembolism; vascular disease; and sex.[22](#jah31638-bib-0022){ref-type="ref"}

Among the 987 patients who achieved TTR~1~ ≥70% and had interpolatable INR values through period 2 (months 10--15), 562 (56.9%) persisted as well‐controlled warfarin users (TTR~2~ ≥70%). Most INR time that was out of range was below INR 2.0, and this pattern worsened in lower TTR categories (Figure [2](#jah31638-fig-0002){ref-type="fig"}). Expanding the definition of good‐quality TTR~2~ to ≥65%, 650 (65.9%) persisted as good‐quality warfarin users (TTR~2~ ≥65%). If the target INR range was expanded to include the full optimal INR range of 1.8 to 3.5 in the subsequent period, 891 (90.3%) achieved a TTR~2~ ≥70%.

![The distribution of TTR values in the second 6‐month period (TTR ~2~, months 10--15) among the 987 warfarin‐treated ATRIA atrial fibrillation cohort patients whose TTR in the first 6‐month period (TTR ~1~: months 4--9) was ≥70% and who continued warfarin with a calculable TTR in period 2. An additional 58 patients had TTR ~1~ ≥70% but discontinued warfarin in period 2. These last patients are included in a sensitivity analysis. Note that the initial 3 months on warfarin (months 1--3) were excluded because time is needed to establish warfarin dosing. The mean percentage of time below INR 2.0 and above INR 3.0, respectively, for the 5 ordered categories of TTR ~2~ were (1) TTR ~2~ ≥70%: 8.6% and 5.4%; (2) TTR ~2~ 65--69%: 20.5% and 12.1%; (3) TTR ~2~ 60--64%: 25.5% and 11.6%; (4) TTR ~2~ 50--59%: 29.3% and 15.6%; and (5) TTR ~2~ \<50%: 48.6% and 16.6%. ATRIA indicates anticoagulation and risk factors in atrial fibrillation; TTR, time in the therapeutic range.](JAH3-5-e003482-g002){#jah31638-fig-0002}

In univariate analyses, TTR (using INR 2.0--3.0, the standard therapeutic range) in the initial period, absence of renal impairment, and absence of heart failure were significantly associated with high‐quality TTR in the subsequent period (Table [4](#jah31638-tbl-0004){ref-type="table-wrap"}). In multivariable analysis, only TTR~1~ ≥90% remained a strong independent predictor of persistent high‐quality warfarin therapy (adjusted odds ratio 1.47, 95% CI 1.07--2.01) (Table [4](#jah31638-tbl-0004){ref-type="table-wrap"}).

###### 

Univariate and Multivariable Correlates of TTR ≥70% in Months 10--15 Among Those With TTR ≥70% in Months 4--9 (n=987)[a](#jah31638-note-0017){ref-type="fn"}

  Variable[b](#jah31638-note-0018){ref-type="fn"}                 n     Patients With TTR ≥70% in Months 10--15, n (%)   Univariate *P* Value[c](#jah31638-note-0019){ref-type="fn"}   Multivariable Odds Ratio (95% CI)[d](#jah31638-note-0020){ref-type="fn"}
  --------------------------------------------------------------- ----- ------------------------------------------------ ------------------------------------------------------------- --------------------------------------------------------------------------
  All                                                             987   562 (56.9)                                       NA                                                            NA
  TTR in months 4--9                                                                                                     0.018                                                         
  70--79%                                                         375   202 (53.9)                                                                                                     Ref
  80--89%                                                         319   173 (54.2)                                       1.03 (0.76--1.39)                                             
  ≥90%                                                            293   187 (63.8)                                       1.47 (1.07--2.01)[e](#jah31638-note-0022){ref-type="fn"}      
  Age                                                                                                                    0.79                                                          
  \<75 y                                                          511   293 (57.3)                                                                                                     
  ≥75 y                                                           476   269 (56.5)                                                                                                     
  Sex                                                                                                                    0.46                                                          
  Men                                                             552   320 (58.0)                                                                                                     
  Women                                                           435   242 (55.6)                                                                                                     
  Race                                                                                                                   0.74                                                          
  White                                                           874   496 (56.8)                                                                                                     
  Other                                                           113   66 (58.4)                                                                                                      
  Diabetes mellitus                                                                                                      0.073                                                         0.80 (0.56--1.13)
  No                                                              823   479 (58.2)                                                                                                     
  Yes                                                             164   83 (50.6)                                                                                                      
  Hypertension                                                                                                           0.24                                                          
  No                                                              418   229 (54.8)                                                                                                     
  Yes                                                             569   333 (58.5)                                                                                                     
  Coronary heart disease                                                                                                 0.69                                                          
  No                                                              717   411 (57.3)                                                                                                     
  Yes                                                             270   151 (55.9)                                                                                                     
  Heart failure                                                                                                          0.012                                                         0.79 (0.59--1.06)
  No                                                              705   419 (59.4)                                                                                                     
  Yes                                                             282   143 (50.7)                                                                                                     
  Peripheral artery disease                                                                                              0.34                                                          
  No                                                              958   548 (57.2)                                                                                                     
  Yes                                                             29    14 (48.3)                                                                                                      
  Renal impairment[e](#jah31638-note-0022){ref-type="fn"}                                                                0.027                                                         0.74 (0.50--1.11)
  No                                                              871   507 (58.2)                                                                                                     
  Yes                                                             116   55 (47.4)                                                                                                      
  Prior stroke                                                                                                           0.89                                                          
  No                                                              895   509 (56.9)                                                                                                     
  Yes                                                             92    53 (57.6)                                                                                                      
  Cancer                                                                                                                 0.63                                                          
  No                                                              865   495 (57.2)                                                                                                     
  Yes                                                             122   67 (54.9)                                                                                                      
  Prior bleed                                                                                                            0.98                                                          
  No                                                              938   534 (56.9)                                                                                                     
  Yes                                                             49    28 (57.1)                                                                                                      
  Beta blockers                                                                                                          0.65                                                          
  No                                                              658   378 (57.4)                                                                                                     
  Yes                                                             329   184 (55.9)                                                                                                     
  Antiarrhythmics                                                                                                        0.45                                                          
  No                                                              881   498 (56.5)                                                                                                     
  Yes                                                             106   64 (60.4)                                                                                                      
  Calcium channel blockers                                                                                               0.31                                                          
  No                                                              753   422 (56.0)                                                                                                     
  Yes                                                             234   140 (59.8)                                                                                                     
  ATRIA score[f](#jah31638-note-0023){ref-type="fn"}                                                                     0.91                                                          
  0--5                                                            472   272 (57.6)                                                                                                     
  6                                                               136   77 (56.6)                                                                                                      
  ≥7                                                              379   213 (56.2)                                                                                                     
  CHA~2~DS~2~‐VASc score[g](#jah31638-note-0024){ref-type="fn"}                                                          0.069                                                         
  0                                                               44    25 (56.8)                                                                                                      Ref
  1                                                               138   91 (65.9)                                        1.53 (0.76--3.07)                                             
  ≥2                                                              805   446 (55.4)                                       1.14 (0.61--2.14)                                             

ATRIA indicates anticoagulation and risk factors in atrial fibrillation; eGFR, estimated glomerular filtration rate; ESRD, end‐stage renal disease; NA, not available; Ref, reference; TTR, time in the therapeutic range.

Included patients had to have a calculable TTR in period 2.

Variables assessed at the start of month 10 of follow‐up.

Univariate *P* values from chi‐square tests.

Variables entered into the multivariable logistic model were TTR in months 4--9, diabetes mellitus, heart failure, and renal impairment.

eGFR \<45 mL/min/1.73 m^2^ or ESRD.

ATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart failure, hypertension, proteinuria, and eGFR \<45 mL/min/1.73 m^2^ or ESRD.[23](#jah31638-bib-0023){ref-type="ref"}

CHA~2~DS~2~‐VASc score includes heart failure; hypertension; age; diabetes mellitus; stroke, transient ischemic attack, or thromboembolism; vascular disease; and sex.[22](#jah31638-bib-0022){ref-type="ref"}

Among patients with TTR~1~ ≥70%, 154 (15.6%) had the poor outcome of a TTR~2~ \<50% (Figure [2](#jah31638-fig-0002){ref-type="fig"}). Only heart failure was significantly associated with deterioration to TTR \<50% in the subsequent period (adjusted odds ratio 1.45, 95% CI 1.00--2.10) (Table [5](#jah31638-tbl-0005){ref-type="table-wrap"}). Of 1045 patients achieving a TTR ≥70% in months 4 to 9, 58 discontinued warfarin in months 10 to 15. If we broadened our definition of poor outcome to the composite of TTR~2~ \<50% or discontinued warfarin, no patient features were significantly related to poor outcome in multivariable models. With this expanded definition of poor outcome, the adjusted odds ratio for heart failure was 1.24 (95% CI 0.89--1.73).

###### 

Univariate and Multivariable Correlates of Markedly Deteriorated TTR (\<50%) Among Those With TTR ≥70% in Months 4--9 (n=987)

  Variable[a](#jah31638-note-0026){ref-type="fn"}                              n     Patients With TTR \<50% in Months 10--15, n (%)   Univariate *P* Value[b](#jah31638-note-0027){ref-type="fn"}   Multivariable Odds Ratio (95% CI)[c](#jah31638-note-0028){ref-type="fn"}
  ---------------------------------------------------------------------------- ----- ------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------------
  All                                                                          987   154 (15.6)                                        NA                                                            NA
  TTR in months 4--9                                                                                                                   0.66                                                          
  70--79%                                                                      375   54 (14.4)                                                                                                       
  80--89%                                                                      319   54 (16.9)                                                                                                       
  ≥90%                                                                         293   46 (15.7)                                                                                                       
  Age                                                                                                                                  0.63                                                          
  \<75 y                                                                       511   77 (15.1)                                                                                                       
  ≥75 y                                                                        476   77 (16.2)                                                                                                       
  Sex                                                                                                                                  0.71                                                          
  Men                                                                          552   84 (15.2)                                                                                                       
  Women                                                                        435   70 (16.1)                                                                                                       
  Race                                                                                                                                 0.47                                                          
  White                                                                        874   139 (15.9)                                                                                                      
  Other                                                                        113   15 (13.3)                                                                                                       
  Diabetes mellitus                                                                                                                    0.92                                                          
  No                                                                           823   128 (15.6)                                                                                                      
  Yes                                                                          164   26 (15.9)                                                                                                       
  Hypertension                                                                                                                         0.83                                                          
  No                                                                           418   64 (15.3)                                                                                                       
  Yes                                                                          569   90 (15.8)                                                                                                       
  Coronary heart disease                                                                                                               0.34                                                          
  No                                                                           717   107 (14.9)                                                                                                      
  Yes                                                                          270   47 (17.4)                                                                                                       
  Heart failure                                                                                                                        0.02                                                          1.45 (1.00--2.10)
  No                                                                           705   98 (13.9)                                                                                                       
  Yes                                                                          282   56 (19.9)                                                                                                       
  Peripheral artery disease                                                                                                            0.43                                                          
  No                                                                           958   151 (15.8)                                                                                                      
  Yes                                                                          29    3 (10.3)                                                                                                        
  Renal impairment[d](#jah31638-note-0030){ref-type="fn"}                                                                              0.18                                                          1.25 (0.75--2.07)
  No                                                                           871   131 (15.0)                                                                                                      
  Yes                                                                          116   23 (19.8)                                                                                                       
  Prior stroke                                                                                                                         0.68                                                          
  No                                                                           895   141 (15.8)                                                                                                      
  Yes                                                                          92    13 (14.1)                                                                                                       
  Cancer                                                                                                                               0.43                                                          
  No                                                                           865   132 (15.3)                                                                                                      
  Yes                                                                          122   22 (18.0)                                                                                                       
  Prior bleed                                                                                                                          0.29                                                          
  No                                                                           938   149 (15.9)                                                                                                      
  Yes                                                                          49    5 (10.2)                                                                                                        
  Beta blockers                                                                                                                        0.62                                                          
  No                                                                           658   100 (15.2)                                                                                                      
  Yes                                                                          329   54 (16.4)                                                                                                       
  Antiarrhythmics                                                                                                                      0.064                                                         0.52 (0.27--1.03)
  No                                                                           881   144 (16.3)                                                                                                      
  Yes                                                                          106   10 (9.4)                                                                                                        
  Calcium channel blockers                                                                                                             0.12                                                          0.72 (0.46--1.11)
  No                                                                           753   125 (16.6)                                                                                                      
  Yes                                                                          234   29 (12.4)                                                                                                       
  ATRIA score at admission[e](#jah31638-note-0031){ref-type="fn"}                                                                      0.33                                                          
  0--5                                                                         472   73 (15.5)                                                                                                       
  6                                                                            136   16 (11.8)                                                                                                       
  ≥7                                                                           379   65 (17.2)                                                                                                       
  CHA~2~DS~2~‐VASc score at admission[f](#jah31638-note-0032){ref-type="fn"}                                                           0.57                                                          
  0                                                                            44    5 (11.4)                                                                                                        
  1                                                                            138   19 (13.8)                                                                                                       
  ≥2                                                                           805   130 (16.1)                                                                                                      

ATRIA indicates anticoagulation and risk factors in atrial fibrillation; eGFR, estimated glomerular filtration rate; ESRD, end‐stage renal disease; NA, not available; TTR, time in the therapeutic range.

Variables assessed at the start of month 10 of follow‐up.

Univariate *P* values from chi‐square tests.

Variables entered into the multivariable logistic model were heart failure, renal impairment, antiarrhythmics, and calcium channel blockers at the start of month 10.

eGFR \<45 mL/min/1.73 m^2^ or ESRD.

ATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart failure, hypertension, proteinuria, and eGFR \<45 mL/min/1.73 m^2^ or ESRD.[23](#jah31638-bib-0023){ref-type="ref"}

CHA~2~DS~2~‐VASc score includes heart failure; hypertension; age; diabetes mellitus; stroke, transient ischemic attack, or thromboembolism; vascular disease; and sex.[22](#jah31638-bib-0022){ref-type="ref"}

Discussion {#jah31638-sec-0010}
==========

Using a large real‐world community cohort of AF patients newly and continuously taking warfarin, we assessed how well good control of anticoagulation persisted. We allowed an initial dose‐finding period of months 1 to 3 and then calculated the TTR in study period 1 (months 4--9). We then focused on patients with high‐quality anticoagulation (ie, TTR ≥70%) in period 1 and followed them over a subsequent 6‐month period (months 10--15). We found that 41% of patients achieved TTR ≥70% in period 1. Of these, 57% persisted at TTR ≥70% in period 2. Another 8.9% maintained a TTR~2~ between 65% and 69%, a range still considered good quality and better than levels seen in recent randomized trials.[24](#jah31638-bib-0024){ref-type="ref"} With the target INR range in period 2 defined as 1.8 to 3.5, fully 90% maintained TTR ≥70%. Empirical evidence shows that the optimal INR range for AF is 1.8 to 3.5, not just 2.0 to 3.0.[7](#jah31638-bib-0007){ref-type="ref"} Only 16% deteriorated to a TTR \<50% (using the standard target of INR 2.0--3.0). Although excellent TTR (ie, ≥90%) predicted continued high TTR levels, no other clinical feature was significantly associated with TTR ≥70% in the second period of warfarin anticoagulation. The presence of heart failure was the only significant predictor of marked deterioration (ie, TTR \<50%) in the second follow‐up period. When we expanded our definition of poor outcome in period 2 to include both TTR \<50% or discontinuing warfarin, no clinical feature was significantly and independently associated with poor outcome. Our results indicate that most patients with well‐controlled warfarin therapy continue to do well.

Because INR levels between 2.0 and 3.0 are associated with low rates of both ischemic stroke and major bleeding, linearly interpolated TTR has become a standard measure of quality of warfarin management.[11](#jah31638-bib-0011){ref-type="ref"} Several clinical trials have provided evidence of warfarin\'s improved efficacy at high TTR levels, usually defined as approximately ≥70%.[12](#jah31638-bib-0012){ref-type="ref"}, [14](#jah31638-bib-0014){ref-type="ref"}, [25](#jah31638-bib-0025){ref-type="ref"} Multiple studies have aimed to identify predictors of TTR, including language, race, sex, age, and medical history, but such patient features account for only a small fraction of the variance of TTR.[26](#jah31638-bib-0026){ref-type="ref"}, [27](#jah31638-bib-0027){ref-type="ref"}, [28](#jah31638-bib-0028){ref-type="ref"}, [29](#jah31638-bib-0029){ref-type="ref"} We found that only impaired renal function was significantly and inversely associated with TTR ≥70% in our first period of follow‐up (months 4--9). Patients with impaired renal function were largely excluded from the trials of novel anticoagulants. These recently developed anticoagulants are not optimal replacements for warfarin in the face of renal insufficiency.[24](#jah31638-bib-0024){ref-type="ref"}, [30](#jah31638-bib-0030){ref-type="ref"}, [31](#jah31638-bib-0031){ref-type="ref"}, [32](#jah31638-bib-0032){ref-type="ref"}

AF patients receiving warfarin now have the opportunity to switch to novel oral anticoagulants. These agents have comparable efficacy for reducing risk of stroke and do not require frequent INR monitoring. They have a clear advantage in reducing rates of intracranial hemorrhage compared with warfarin by approximately four per thousand per year.[33](#jah31638-bib-0033){ref-type="ref"} Although there is some inconsistency across trials,[34](#jah31638-bib-0034){ref-type="ref"} warfarin at TTR ≥70% appears to be equivalent to novel anticoagulants in terms of preventing stroke and systemic embolism, with increased risk of hemorrhagic stroke countered by reduced risk of ischemic stroke.[12](#jah31638-bib-0012){ref-type="ref"}, [14](#jah31638-bib-0014){ref-type="ref"} There may still be a small benefit favoring novel agents in terms of nonstroke intracranial hemorrhage, partially balanced by an increased risk of gastrointestinal hemorrhage.[33](#jah31638-bib-0033){ref-type="ref"} Patients are likely to incur greater out‐of‐pocket costs with novel agents than with warfarin.[35](#jah31638-bib-0035){ref-type="ref"} Moreover, patients may prefer to continue taking warfarin.[36](#jah31638-bib-0036){ref-type="ref"} Our results are directly relevant to patients deciding whether to continue warfarin or to seek a substitute and for whom the convenience of novel agents is not an important factor. Our results support a watchful waiting approach for AF patients who have achieved a TTR ≥70% when taking warfarin because most of these patients will continue to do well. Providers should be particularly attentive to patients with heart failure because such patients are at modestly increased risk of substantial deterioration in TTR.[37](#jah31638-bib-0037){ref-type="ref"}

Our study represents the experience of AF patients in a community‐based cohort within a large, well‐resourced, integrated health care delivery system. Management of warfarin was coordinated predominantly through dedicated anticoagulation management services. Our results should apply broadly to patients whose anticoagulation was managed in a similar fashion. It is not clear whether our findings generalize to other, less formal systems of managing anticoagulation. High‐quality warfarin anticoagulation depends on patients obtaining frequent INR tests. Patient‐ or system‐level barriers to such a testing regimen will pose a challenge to maintaining TTR levels ≥70%. Our results strictly apply to AF patients at the 9‐month mark after initiating warfarin therapy. Although we assume these results apply more broadly to all AF patients after a prolonged period (ie, 6 months) of high‐quality warfarin treatment, validation of this assumption awaits further study.

Conclusion {#jah31638-sec-0011}
==========

Overall, 57% of AF patients with high‐quality 6‐month TTR after initiating warfarin (excluding an initial 3‐month dose‐finding period) maintained TTR ≥70% over the subsequent 6 months. A minority deteriorated to very poor TTR. Patient features do not strongly predict deterioration, although heart failure moderately increases this risk. Our analyses support watchful waiting for AF patients with initial high‐quality warfarin anticoagulation before considering switching to a novel anticoagulant.
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**Table S1.** Characteristics of Patients With and Without 9 Months of Continuous Warfarin Use Following Initial Prescription
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